Revenue Breakdown
Composition ()
No data
Revenue Streams
NovaBay Pharmaceuticals Inc (NBY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Avenova, accounting for 88.5% of total sales, equivalent to $2.12M. Other significant revenue streams include Other products and Other revenue, net. Understanding this composition is critical for investors evaluating how NBY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Comparative Benchmarking
In the context of the broader market, NBY competes directly with industry leaders such as EDSA and MGX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NBY's gross margin of N/A stands against EDSA's N/A and MGX's 100.00%. Such benchmarking helps identify whether NovaBay Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
